As of 2025-12-25, the Intrinsic Value of GT Biopharma Inc (GTBP) is -5.48 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.81 USD, the upside of GT Biopharma Inc is -781.36%.
Based on its market price of 0.81 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 781.36%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -5.48 - -5.48 | -5.48 | -781.36% |
| P/E | (24.05) - (26.33) | (26.93) | -3445.5% |
| DDM - Stable | (7.09) - (28.53) | (17.81) | -2312.0% |
| DDM - Multi | (7.21) - (23.60) | (11.16) | -1486.3% |
| Market Cap (mil) | 8.57 |
| Beta | 0.10 |
| Outstanding shares (mil) | 10.64 |
| Enterprise Value (mil) | 6.04 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.15% |
| Cost of Debt | 5.00% |
| WACC | 7.41% |